Specific immune recognition of pancreatic carcinoma by patient-derived CD4 and CD8 T cells and its improvement by interferon-γ

International Journal of Oncology

Volumn 28, Issue 6, 2006, Pages 1419-1428

  Schmitz Winnenthal, F H ^a   Galindo Escobedo, L V ^a   Beckhove, Philipp ^b   Schirrmacher, V ^b   Bucur, M ^b   Ziouta, Y ^b   Volk, C ^a   Schmied, B ^a   Koch, M ^a   Antolovic, D ^a   Weitz, J ^a   Buchler M W ^a   Z'Graggen, K ^c  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c Klinik Beau Site   (Switzerland)

Author keywords

Antigen presentation; Immunotherapy; Interferon ; Pancreatic cancer; Tumor specific T cells

Indexed keywords

GAMMA INTERFERON; HLA ANTIGEN CLASS 1; HLA D ANTIGEN; INTERLEUKIN 4;

AGED; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFECT; FEMALE; HUMAN; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MIDDLE AGED; PANCREAS TUMOR;

AGED; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA-D ANTIGENS; HUMANS; IMMUNOLOGIC MEMORY; INTERFERON TYPE II; INTERLEUKIN-4; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS;

EID: 33747117063     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.28.6.1419     Document Type: Article

References (46)

1. Lowenfels AB and Maisonneuve P: Epidemiology and prevention of pancreatic cancer. Jpn J Clin Oncol 34: 238-244, 2004.
2. Neptolemus JP, Raraty MG, Ghaneh P, et al: Adjuvante und additive therapie beim pankreaskarzinom. Chirurg 74: 191-201, 2003.
3. Warshaw AL and Fernandez del Castillo C: Pancreatic carcinoma. N Eng J Med 326: 455-465, 1992.
4. Czito BG, Willett CG, Clark JW and Fernandez DC: Current perspectives on locally advanced pancreatic cancer. Oncology (Huntingt) 14: 1535-1545, 2000.
5. + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 99: 16168-16173, 2002.
6. Kubuschok B, Xie X, Jesnowski R, et al: Expression of cancer testis antigens in pancreatic carcinoma cell lines, pancreatic adenocarcinoma and chronic pancreatitis. Int J Cancer 109: 568-575, 2004.
7. Feuerer M, Beckhove P, Bai L, et al: Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. Nat Med 7: 452-458, 2001. (Pubitemid 32298548)
8. Choi C, Witzens M, Bucur M, et al: Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma. Blood 105: 2132-2134, 2005.
9. + memory T cells. Cancer Res 63: 5582-5586, 2003.
10. Ito M, Shichijo S, Tsuda N, et al: Molecular basis of T cell-mediated recognition of pancreatic cancer cells. Cancer Res 61: 2038-2046, 2001.
11. Konopitzky R, Konig U, Meyer RG, Sommergruber W, Wolfel T and Schweighoffer T: Identification of HLA-A*0201-restricted T cell epitopes derived from the novel overexpressed tumor antigen calcium-activated chloride channel 2. J Immunol 169: 540-547, 2002.
12. Momburg F, Ziegler A, Harpprecht J, Möller P, Moldenhauer G and Hämmerling G: Selective loss of HLA-A or HLA-B antigen in colon carcinoma. J Immunol 142: 352-358, 1989.
13. Garrido F, Cabrera T, Concha A, Glew S, Ruiz-Cabello F and Stern PL: Natural history of HLA expression during tumor development. Immunol Today 14: 491-499, 1993.
14. Cabrera T, Maleno I, Lopez-Nevot MA, et al: High frequency of HLA-B44 allelic losses in human solid tumors. Hum Immunol 64: 941-950, 2003.
15. Daar AS, Fuggle SV, Fabre JW, et al: The detailed distribution of HLA-A, B, C antigens in normal human organs. Transplantation 38: 287-292, 1984.
16. Ruiter DJ, Mattijssen V, Broecker EB, et al: MHC antigens in human melanomas. Semin Cancer Biol 2: 35-45, 1991.
17. Ma XC, Hattori T, Kushima R, et al: Expression of HLA-class II antigen in gastric carcinomas. Its relationship to histopathological grade, lymphocyte infiltration and five-year survival rate. Acta Oncol 33: 187-190, 1994.
18. Dissanayake SK, Tuera N and Ostrand-Rosenberg S: Presentation of endogenously synthesized MHC class II-restricted epitopes by MHC class II cancer vaccines is independent of transporter associated with Ag processing and the proteasome. J Immunol 174: 1811-1819, 2005.
19. Dani A, Chaudhry A, Mukherjee P, et al: The pathway for MHCII-mediated presentation of endogenous proteins involves peptide transport to the endo-lysosomal compartment. J Cell Sci 117: 4219-4230, 2004.
20. + T cells. Cancer Res 63: 4095-4100, 2003.
21. Thornhill MH, Wellicome SM, Mahiouz DL, Lanchbury JS, Kyan-Aung U and Haskard DO: Tumor necrosis factor combines with IL-4 or IFN-gamma to selectively enhance endothelial cell adhesiveness for T cells. The contribution of vascular cell adhesion molecule-1-dependent and -independent binding mechanisms. J Immunol 146: 592-598, 1991.
22. Younes E, Haas GP, Visscher D, Pontes JE, Puri RK and Hillman GG: Intralesional treatment of established murine primary renal tumor with interleukin-4: localized effect on primary tumor with no impact on metastases. J Urol 153: 490-493, 1995.
23. Giacomini P, Tecce R, Gambari R, Sacchi A, Fisher PB and Natali PG: Recombinant human IFN-gamma, but not IFN-alpha or IFN-beta, enhances MHC- and non-MHC-encoded glycoproteins by a protein synthesis-dependent mechanism. J Immunol 140: 3073-3081, 1988.
24. Rosa FM, Cochet MM and Fellous M: Interferon and major histocompatibility complex genes: a model to analyse eukaryotic gene regulation? Interferon 7: 48-87, 1986.
25. Niederwieser D, Auböck J, Tromppmair J, et al: IFN-mediated induction of MHC antigen expression on human keratinocytes and its influence on in vitro alloimmune responses. J Immunol 140: 2556-2564, 1988.
26. Shaw AR, Chan JK, Reid S and Seehafer J: HLA-DR synthesis induction and expression in HLA-DR-negative carcinoma cell lines of diverse origins by interferon-gamma but not by interferon-beta. J Natl Cancer Inst 74: 1261-1268, 1985.
27. Giacomini P, Fisher PB, Duigou GJ, Gambari R and Natali PG: Regulation of class II MHC gene expression by interferons: insights into the mechanism of action of interferon. Anticancer Res 8: 1153-1161, 1988.
28. Bornstein J, Lahat N, Kinarty A, Revel M, Abramovici H and Shapiro S: Interferon-beta and gamma, but not tumor necrosis factor-alpha, demonstrate immunoregulatory effects on carcinoma cell lines infected with human papillomavirus. Cancer 79: 924-934, 1997.
29. Nouri AM, Hussain RF, Dos Santos AV, Gillott DJ and Oliver RT: Induction of MHC antigens by tumour cell lines in response to interferons. Eur J Cancer 28A: 1110-1115, 1992.
30. Barez S, Boumpas DT, Percopo CM, Anastassiou ED, Hooks JJ and Detrick B: Modulation of major histocompatibility complex class 1 genes in human retinoblastoma cells by interferons. Invest Ophthalmol Vis Sci 34: 2613-2621, 1993.
31. Wolfel T, Herr W, Coulie P, Schmitt U, Meyer zum Buschenfelde KH and Knuth A: Lysis of human pancreatic adenocarcinoma cells by autologous HLA-class I-restricted cytolytic T-lymphocyte (CTL) clones. Int J Cancer 54: 636-644, 1993.
32. Ostrand-Rosenberg S: Tumor immunotherapy: the tumor cell as an antigen-presenting cell. Curr Opin Immunol 6: 722-727, 1994.
33. Ostrand-Rosenberg S, Thakur A and Clements V: Rejection of mouse sarcoma cells after transfection of MHC class II genes. J Immunol 144: 4068-4071, 1990.
34. + tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas 28: e26-e31, 2004.
35. Beckhove P, Feuerer M, Dolenc M, et al: Specifically activated memory T cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors. J Clin Invest 114: 67-76, 2004.
36. Ramal LM, Maleno I, Cabrera T, et al: Molecular strategies to define HLA haplotype loss in microdissected tumor cells. Hum Immunol 61: 1001-1012, 2000.
37. Solomayer EF, Feuerer M, Bai L, et al: Influence of adjuvant hormone therapy and chemotherapy on the immune system analysed in the bone marrow of patients with breast cancer. Clin Cancer Res 9: 174-180, 2003.
38. Bai L, Beckhove P, Feuerer M, et al: Cognate interactions between memory T cells and tumor antigen-presenting dendritic cells from bone marrow of breast cancer patients: bidirectional cell stimulation, survival and antitumor activity in vivo. Int J Cancer 103: 73-83, 2003.
39. Von Bernstorff W, Voss M, Freichel S, et al: Systemic and local immunosuppression in pancreatic cancer patients. Clin Cancer Res 7: 925S-932S, 2001.
40. Von Bernstorff W, Sapanjaard RA, Chan AK, et al: Pancreatic cancer cells can evade immune surveillance via non-functional Fas (APO/CD95) receptors and aberrant expression of functional Fas ligand. Surgery 125: 73-84, 1999.
41. Scupoli MT, Sartoris S, Tosi G, et al: Expression of MHC class I and class II antigens in pancreatic adenocarcinomas. Tissue Antigens 48: 301-311, 1996.
42. McDermott DF and Atkins MB: Application of IL-2 and other cytokines in renal cancer. Expert Opin Biol Ther 4: 455-468, 2004.
43. Windbichler GH, Hausmaninger H, Stummvoll W, et al: Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Br J Cancer 82: 1138-1144, 2000.
44. Aki M, Shimbara N, Takashina M, et al: Interferon-gamma induces different subunit organizations and functional diversity of proteasomes. J Biochem 115: 257-269, 1994.
45. Stout RD, Jiang C, Matta B, Tietzel I, Watkins SK and Suttles J: Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences. J Immunol 175: 342-349, 2005.
46. + T cell to a fully functional tumor killer cell. Cancer Res 62: 6438-6441, 2002.